PharmaFocus Today – Page 38 – media

First ESC statement on mental health and heart disease promotes integrated care

A new ESC Clinical Consensus Statement is calling for greater awareness of the multidirectional relationship between mental health conditions and cardiovascular disease to improve patient health. The first ever ESC Clinical Consensus Statement to be developed on this topic was published today at ESC Congress 2025. The Consensus Statement recommends that mental health symptoms are systematically screened for during cardiovascular care, and cardiovascular risk is routinely assessed for those being treated for mental health conditions. While poor mental health can be a contributory factor to cardiovascular disease, people living with cardiovascular disease are also at greater risk of poor mental health. Patients experiencing both cardiovascular disease and a mental health condition have worse health outcomes. The Consensus Statement has been produced by an international panel of experts that includes co-Chairpersons Professor Héctor Bueno, from the National Cardiovascular Research Center (CNIC) and the Cardiology Department, Hospital Universitario 12 de Octubre, Madrid, ...
- Source: drugdu
- 98
- September 1, 2025
Another Phase III clinical study of Tetasip is successful

On August 27, Rongchang Biopharma announced that its independently developed world’s first BLyS/APRIL dual-target fusion protein innovative drug Taitasip (trade name: Tai Ai®) for the treatment of primary immunoglobulin A (IgA) nephropathy reached the primary study endpoint of Phase A in the domestic Phase III clinical study. Study results showed that compared with the placebo group, patients in the tetasip group experienced a 55% reduction in 24-hour urine protein-to-creatinine ratio (UPCR) at week 39 of treatment (P<0.0001), demonstrating good tolerability and safety. Rongchang Biopharma stated that it will submit a marketing application to the National Medical Products Administration (NMPA) as soon as possible, and detailed data will be presented at a major international academic conference. This multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial enrolled 318 adult patients with IgA nephropathy receiving standard treatment. Tetasipir was administered at a dose of 240 mg subcutaneously once weekly. The study aimed to ...
- Source: drugdu
- 99
- September 1, 2025
A world first! Sino Biopharmaceutical’s oral targeted drug, Sanhetu, for advanced non-small cell lung cancer with HER2 mutations has been approved

On August 29, Boehringer Ingelheim and Sino Biopharmaceutical (01177.HK) jointly announced that their jointly promoted drug, Zongertinib (Chinese generic name: Zongertinib tablets, English generic name: zongertinib), has been officially approved by the China National Medical Products Administration for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have activating HER2 (ERBB2) mutations and have received at least one previous systemic therapy. Sanhetu® is the world’s first and currently only approved oral HER2 tyrosine kinase inhibitor. Its conditional approval in China is based on positive results from the Beamion-LUNG 1 study, which evaluated the efficacy and safety of zonectinib in patients with advanced non-small cell lung cancer (NSCLC) harboring a HER2 (ERBB2) mutation. Data from cohort 1 (N=75) of previously treated patients demonstrated an objective response rate (ORR) of 71% (95% CI: 60-80), including 7% complete responses, and a disease control rate (DCR) ...
- Source: drugdu
- 89
- September 1, 2025
Scientists develop new mRNA vaccine platform that can significantly enhance the body’s immune response

Yale University researchers have developed a novel mRNA vaccine platform designed to significantly enhance immune responses, improve the effectiveness of mRNA vaccines, and expand their potential for preventing and treating a variety of diseases. The study, published in the latest issue of Nature Biomedical Engineering, demonstrates that this vaccine platform technology could make future mRNA vaccines more reliable and effective. mRNA vaccines have become increasingly popular in recent years. Their principle is to provide genetic instructions to human cells, enabling them to produce specific viral proteins on their own, thereby triggering an immune response. However, this technology has limited effectiveness in treating certain diseases, prompting researchers to continuously optimize its delivery system. Researchers have found that the key to the effectiveness of mRNA vaccines lies in whether the antigens can be effectively recognized by the immune system. Antigens must appear on the cell surface to be detected by the immune ...
- Source: drugdu
- 109
- September 1, 2025
Difluprednate API Approved, Strengthening Advantages of Integrated API and Pharmaceutical Preparations

August 29, Jinyao Pharmaceutical(600488) issued an announcement. Recently, the company received the ” Chemical Raw Materials ” certificate for difluprednate approved by the State Food and Drug Administration.Approval of the Drug Marketing Application. It is understood that difluprednate is a topical corticosteroid that can inhibit inflammatory responses caused by various irritants. Currently, the main dosage form on the market is eye drops, primarily used to treat inflammation and pain associated with eye surgery. According to statistics from the IQVIA database, the global sales of difluprednate preparations (including single and compound preparations) in 2023 and 2024 will be US$49 million and US$41 million, respectively. The announcement indicates that the company submitted its registration application for difluprednate API to the National Medical Products Administration (NMPA) in August 2020 and was accepted. From June to October 2022, the company completed the submission of supplementary documentation as required by the notice and recently received ...
- Source: drugdu
- 86
- September 1, 2025
Healthy gut bacteria capsules show long-term benefits for obese teenagers

Can a capsule of healthy gut bugs change the future of obesity treatment? New findings from the University of Auckland’s Liggins Institute suggest it might. Eight years ago, 87 obese adolescents took part in a groundbreaking study to see whether fecal transfer (taking ‘good’ gut bacteria from healthy donors and giving them in capsule form to people with a less healthy microbiome) would make a difference to their health and weight. Four years later, a follow-up study, published this week in the world-leading scientific journal Nature Communications , suggests some significant health benefits from that single gut bugs transfer. In particular, the original overweight teens who received the transfer had reduced risk for a bunch of metabolic changes which can lead to heart disease, stroke and diabetes, compared with the participants who received the placebo. Obesity is a significant health problem in New Zealand and elsewhere in the world. In ...
- Source: drugdu
- 110
- August 29, 2025
Fatty Foods Might Contribute To Childhood Asthma

By Dennis Thompson HealthDay ReporterTHURSDAY, Aug. 28, 2025 (HealthDay News) — Fatty foods might contribute to asthma in children, a new study says. Fats found in certain foods are linked to neutrophilic asthma, a non-allergic type of asthma triggered by microbial and bacterial proteins, researchers reported Aug. 27 in the journal Science Translational Medicine. Specifically, a type of saturated fatty acid called stearic acid – often found in animal fat and processed foods – appears to start a chain reaction that can lead to neutrophilic asthma, researchers said. “Prior to this study, many suspected that childhood obesity was causing this form of asthma,” said senior researcher Dr. David Hill, an attending physician in allergy and immunology at Children’s Hospital of Philadelphia. “However, we were observing neutrophilic asthma in children who weren’t obese, which is why we suspected there might be another mechanism,” Hill said in a news release. “What we ...
- Source: drugdu
- 127
- August 29, 2025
Clinical research of SGC001, a drug in which Regeneron Biopharma holds a stake, is progressing smoothly.

On August 28, Rejing Bio(688068) issued an announcement that it recently received a request from a joint venture company for an innovative drugA progress report on the Phase I clinical study of SGC001 injection. The project has completed a Phase Ia clinical study in healthy volunteers, and the Phase Ib clinical study in patients with anterior ST-segment elevation myocardial infarction is progressing smoothly. Clinical observations of all subjects have been completed, and the clinical study was unblinded on August 27. SGC001 injection, developed jointly by Sungene’s R&D team and other institutions, is indicated for the emergency treatment of patients with acute myocardial infarction. The drug’s clinical trial application has been approved by the FDA and CDE, and it received FDA Fast Track designation in March 2025. Currently, complete efficacy and safety information from the Phase Ib trial will be disclosed in the official data analysis report, and will not have ...
- Source: drugdu
- 80
- August 29, 2025
Walvax Biopharma’s 23-valent pneumococcal vaccine enters the Latin American market for the first time

Recently, Yunnan Walvax BioThe 23-valent pneumococcal polysaccharide vaccine ( hereinafter referred to as ” 23-valent pneumococcal vaccine”) produced by Yuxi Walvax Biotechnology Co. , Ltd., a subsidiary of Walvax Biotechnology Co., Ltd. (hereinafter referred to as “Walvax Biotechnology”), has completed its first export delivery to El Salvador. This milestone event marks the first export of Walvax Biotechnology to El Salvador.The product officially entered the Latin American market, further expanding its global layout. According to data disclosed by Walvax Bio, as the world’s first preservative-free 23-valent pneumococcal polysaccharide vaccine, this product is suitable for children over 2 years old and high-risk adults. The cumulative global sales volume has exceeded 14 million doses. As of now, Walvax Bio has built a diversified global vaccine supply network. Its products, including 13-valent pneumococcal polysaccharide conjugate vaccine, bivalent human papillomavirus vaccine (Pichia pastoris), 23-valent pneumococcal vaccine, ACYW135 group meningococcal polysaccharide vaccine, group A and group C meningococcal ...
- Source: drugdu
- 121
- August 29, 2025
Yabao Pharmaceutical’s subsidiary, SY-005 Injection, has been approved for clinical trials in the treatment of gliomas.

On August 25, Yabao Pharmaceutical(600351) issued an announcement that its controlling subsidiary Suzhou Yabao Pharmaceutical Research and Development Co., Ltd. recently received the “Drug Clinical Trial Approval Notice” for the new indication of SY-005 injection approved and issued by the National Medical Products Administration. The approval notice allows the clinical trial of SY-005 injection for the treatment of neurological deficits after glioma surgery. The application is for the treatment of neurological deficits after glioma surgery, and the drug registration classification is a therapeutic biological product.Category 1. As of the date of this announcement, the company has invested approximately RMB 127 million in R&D for the SY-005 project. SY-005 is an innovative recombinant protein .In November 2018, the company received approval for a clinical trial for the treatment of sepsis, and this indication is currently in Phase II clinical trials. Glioma is the most common primary intracranial malignant tumor, and postoperative ...
- Source: drugdu
- 104
- August 29, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.